US-based INOVA Diagnostics has launched QUANTA Lite Calprotectin, a new US Food and Drug Administration (FDA) cleared assay to aid diagnosis of inflammatory bowel disease (IBD).

The new assay can also help differentiate IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.

The new QUANTA Lite Calprotectin is a quantitative enzyme linked immunosorbent assay (ELISA) that detects calprotectin levels.

The company said accurate detection of calprotectin levels in stool can provide critical information to physicians determining the suitable care of patients suffering from gastrointestinal disorders.

Launch of this new assay further expands the INOVA Diagnostics portfolio in the area of autoimmune gastrointestinal disorders.

INOVA Diagnostics vice president of Research and Development Michael Mahler said the compay is happy to launch this high performing assay to meet the increasing demand from laboratories worldwide.

"Gastrointestinal pain is a common reason for seeking medical attention. Inaccurate diagnosis at the screening level can contribute to unnecessary procedures and increased healthcare costs," Mahler said.

"The QUANTA Lite Calprotectin assay can improve patient care while potentially reducing overall costs."

The company manufactures IVD systems and reagents for autoimmune disease that are used in clinical laboratories and hospitals across the world.

INOVA Diagnostics CEO Roger Inglès said that the benefits of fecal calprotectin testing are being recognized by healthcare systems around the world as evidenced by the recent recommendation from the National Institute for Health and Care Excellence (NICE) in the UK.

"As a worldwide leader in the autoimmunity in vitro diagnostics (IVD) market, INOVA Diagnostics is perfectly positioned to quickly increase awareness and adoption of this important new test across the globe," Inglès said.